MSD Escapes Action By UK Competition Body Over Remicade Discount Scheme
Executive Summary
The UK Competition and Markets Authority has announced that there are “no grounds for action” against MSD in relation to a discount scheme the company introduced in England to fend off biosimilar competition for Remicade. But the competition watchdog had some words of warning for other companies considering discount schemes designed to protect a dominant market position.
You may also be interested in...
Canadian Authorities Say Janssen Did Not Choke Competition For Infliximab – But Will Keep Spotlight On Originator Abuse Of Power
In contrast to a US court, the competition authority in Canada has not found evidence that Janssen abused its power in the infliximab market and unlawfully stymied competition from Pfizer’s and Merck’s biosimilars. However, given the relative immaturity of the Canadian biosimilars market, the Competition Bureau said it would continue to watch closely as the market develops.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.
EU Warns Of Life-Threatening Interactions Between Paxlovid & Some Immunosuppressants
The EU’s pharmacovigilance committee says that a review of the available evidence showed that in several cases, blood levels of immunosuppressants increased rapidly to toxic levels in patients who were taking the Pfizer drug.